282 related articles for article (PubMed ID: 27596109)
1. Clinical approach to diffuse large B cell lymphoma.
Caimi PF; Hill BT; Hsi ED; Smith MR
Blood Rev; 2016 Nov; 30(6):477-491. PubMed ID: 27596109
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
Walji M; Assouline S
Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
[TBL] [Abstract][Full Text] [Related]
3. Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies.
Pilorge S; Harel S; Ribrag V; Larousserie F; Willems L; Franchi P; Legoff M; Biau D; Anract P; Roux C; Blanc-Autran E; Delarue R; Gisselbrecht C; Ketterer N; Recher C; Bonnet C; Peyrade F; Haioun C; Tilly H; Salles G; Brice P; Bouscary D; Deau B; Tamburini J
Leuk Lymphoma; 2016 Dec; 57(12):2820-2826. PubMed ID: 27118302
[TBL] [Abstract][Full Text] [Related]
4. De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.
Alinari L; Gru A; Quinion C; Huang Y; Lozanski A; Lozanski G; Poston J; Venkataraman G; Oak E; Kreisel F; Park SI; Matthews S; Abramson JS; Iris Lim H; Martin P; Cohen JB; Evens A; Al-Mansour Z; Singavi A; Fenske TS; Blum KA
Am J Hematol; 2016 Jun; 91(4):395-9. PubMed ID: 26800311
[TBL] [Abstract][Full Text] [Related]
5. Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy.
Jamil MO; Mehta A
Expert Rev Hematol; 2016 May; 9(5):471-7. PubMed ID: 26808217
[TBL] [Abstract][Full Text] [Related]
6. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
7. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
Matsumoto T; Hara T; Shibata Y; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Goto N; Kito Y; Kasahara S; Yamada T; Sawada M; Miyazaki T; Takami T; Takeuchi T; Moriwaki H; Tsurumi H
Hematol Oncol; 2017 Sep; 35(3):288-295. PubMed ID: 26999778
[TBL] [Abstract][Full Text] [Related]
8. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome.
Larouche JF; Berger F; Chassagne-Clément C; Ffrench M; Callet-Bauchu E; Sebban C; Ghesquières H; Broussais-Guillaumot F; Salles G; Coiffier B
J Clin Oncol; 2010 Apr; 28(12):2094-100. PubMed ID: 20308668
[TBL] [Abstract][Full Text] [Related]
9. Managing early failures with R-CHOP in patients with diffuse large B-cell lymphoma.
Camus V; Tilly H
Expert Rev Hematol; 2017 Dec; 10(12):1047-1055. PubMed ID: 27791447
[TBL] [Abstract][Full Text] [Related]
10. Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary.
Morrison VA; Hamlin P; Soubeyran P; Stauder R; Wadhwa P; Aapro M; Lichtman SM
Ann Oncol; 2015 Jun; 26(6):1058-1068. PubMed ID: 25635006
[TBL] [Abstract][Full Text] [Related]
11. Interim PET Scans in Diffuse Large B-Cell Lymphoma: Is It Ready for Prime Time?
Bolshinsky M; Nabhan C
Clin Lymphoma Myeloma Leuk; 2016 Dec; 16(12):655-661. PubMed ID: 27693134
[TBL] [Abstract][Full Text] [Related]
12. The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase.
Kim YR; Kim SJ; Cheong JW; Yang DH; Lee H; Eom HS; Sung YO; Kim HJ; Kang HJ; Lee WS; Park Y; Yang WI; Min YH; Kim JS
Ann Hematol; 2016 Sep; 95(9):1491-501. PubMed ID: 27324387
[TBL] [Abstract][Full Text] [Related]
13. Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma.
Chiappella A; Santambrogio E; Castellino A; Nicolosi M; Vitolo U
Expert Rev Hematol; 2017 Aug; 10(8):697-705. PubMed ID: 28665232
[TBL] [Abstract][Full Text] [Related]
14. Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.
Zhang S; Zhang T; Liu H; Zhao J; Zhou H; Su X; Liu X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; He J; Wang X; Zhang H
Br J Haematol; 2022 Feb; 196(3):617-628. PubMed ID: 34664256
[TBL] [Abstract][Full Text] [Related]
15. Ocular adnexal diffuse large B-cell lymphoma: a multicenter international study.
Munch-Petersen HD; Rasmussen PK; Coupland SE; Esmaeli B; Finger PT; Graue GF; Grossniklaus HE; Honavar SG; Khong JJ; McKelvie PA; Mulay K; Prause JU; Ralfkiaer E; Sjö LD; Sniegowski MC; Vemuganti GK; Heegaard S
JAMA Ophthalmol; 2015 Feb; 133(2):165-73. PubMed ID: 25393033
[TBL] [Abstract][Full Text] [Related]
16. Diffuse large B-cell lymphoma: is there a place for autologous hematopoietic stem cell transplant in first remission in the era of chemo-immunotherapy?
Nabhan C; Mehta J
Leuk Lymphoma; 2012 Oct; 53(10):1859-66. PubMed ID: 22448919
[TBL] [Abstract][Full Text] [Related]
17. Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients.
Zinzani PL; Broccoli A; Stefoni V; Musuraca G; Abruzzese E; De Renzo A; Cantonetti M; Bacci F; Baccarani M; Pileri SA
Cancer; 2010 Dec; 116(24):5667-75. PubMed ID: 20737566
[TBL] [Abstract][Full Text] [Related]
18. Diffuse large B-cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.
Wight J; Hamad N; Campbell BA; Ku M; Lee K; Rose H; Armytage T; Latimer M; Lee HP; Lee ST; Dickinson M; Khor R; Verner E
Intern Med J; 2022 Sep; 52(9):1609-1623. PubMed ID: 34532916
[TBL] [Abstract][Full Text] [Related]
19. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.
Bartlett NL; Smith MR; Siddiqi T; Advani RH; O'Connor OA; Sharman JP; Feldman T; Savage KJ; Shustov AR; Diefenbach CS; Oki Y; Palanca-Wessels MC; Uttarwar M; Li M; Yang J; Jacobsen ED
Leuk Lymphoma; 2017 Jul; 58(7):1607-1616. PubMed ID: 27868471
[TBL] [Abstract][Full Text] [Related]
20. Management of relapsed/refractory DLBCL.
Sarkozy C; Sehn LH
Best Pract Res Clin Haematol; 2018 Sep; 31(3):209-216. PubMed ID: 30213390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]